Active Not RecruitingNCT06864988
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
PHASE3 · 480 planned enrolment
- Countries listed
- 2
- Registry update
- June 1, 2026
Registry Intervention View
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Trial registrations containing the exact intervention label EYLEA® (aflibercept) Injection 2 mg (0.05mL).
Exact registry label · Not reported
4 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
1 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
Not Yet RecruitingNCT07557121
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
PHASE2 · 35 planned enrolment
- Countries listed
- 0
- Registry update
- April 29, 2026
RecruitingNCT07064759
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
PHASE3 · 480 planned enrolment
- Countries listed
- 14
- Registry update
- April 16, 2026
CompletedNCT05275205
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
PHASE2 · 51 planned enrolment
- Countries listed
- 1
- Registry update
- August 7, 2024